

# Wolfram PÄjnisch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7021100/publications.pdf>

Version: 2024-02-01

62  
papers

561  
citations

758635

12  
h-index

642321

23  
g-index

62  
all docs

62  
docs citations

62  
times ranked

743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. <i>British Journal of Haematology</i> , 2008, 143, 191-200.	1.2	78
2	Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 1757-1765.	0.8	57
3	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1405-1412.	1.2	41
4	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1937-1946.	1.2	35
5	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1189-1197.	1.3	34
6	Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 499-508.	1.2	33
7	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1947-1956.	1.2	30
8	Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial <scp>OSHO</scp> â€“ #077. <i>British Journal of Haematology</i> , 2013, 162, 202-209.	1.2	28
9	Prognostic impact of the CD34+/CD38âˆ’ cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 388-396.	2.0	25
10	Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>HemaSphere</i> , 2019, 3, e167.	1.2	20
11	High <i>BAALC</i> copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. <i>Oncotarget</i> , 2017, 8, 87944-87954.	0.8	19
12	Ixazomibâ€“Thalidomideâ€“Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	2.9	17
13	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	0.6	14
14	High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. <i>Haematologica</i> , 2020, 105, e507.	1.7	12
15	Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2013-2022.	1.2	11
16	Bendamustine in the treatment of multiple myeloma: Results and future perspectives. <i>Seminars in Oncology</i> , 2002, 29, 23-26.	0.8	11
17	Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2545-2553.	1.2	10
18	Bone mineral density in patients with systemic mastocytosis: correlations with clinical and histopathological features. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 52-57.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Treatment with Bendamustine, Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Phase I Clinical Trial.. Blood, 2006, 108, 3564-3564.	0.6	8
20	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.. Journal of Clinical Oncology, 2018, 36, 8019-8019.	0.8	8
21	Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Journal of Cancer Research and Clinical Oncology, 2017, 143, 2049-2058.	1.2	7
22	Comparison of nonâ€myeloablative and reducedâ€intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American Journal of Hematology, 2019, 94, 1344-1352.	2.0	7
23	Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany. Oncology Research and Treatment, 2020, 43, 449-459.	0.8	6
24	Pretreatment CD34+/CD38â€ Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1560-1566.	2.0	5
25	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. Blood, 2016, 128, 1066-1066.	0.6	5
26	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. Cancer, 2021, 127, 3413-3421.	2.0	4
27	Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma.. Blood, 2007, 110, 2723-2723.	0.6	4
28	Can Diagnostic Low-dose Whole-body CT Reflect Bone Marrow Findings in Systemic Mastocytosis?. Anticancer Research, 2020, 40, 1015-1022.	0.5	3
29	Reduced alpha diversity of the oral microbiome correlates with short progressionâ€free survival in patients with relapsed/refractory multiple myeloma treated with ixazomibâ€based therapy (AGMT MM 1), Tj ETQq1o14.784334 rgBT, O		
30	Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV). Journal of Cancer Research and Clinical Oncology, 2021, 147, 2349-2359.	1.2	3
31	Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial. Blood, 2016, 128, 3335-3335.	0.6	3
32	Bone mineral density in patients with systemic mastocytosis: correlations with clinical and histopathological features. Clinical and Experimental Rheumatology, 2021, 39, 52-57.	0.4	3
33	Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study. Blood, 2020, 136, 15-16.	0.6	2
34	Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.. Blood, 2005, 106, 1851-1851.	0.6	2
35	Characteristics of Immunoglobulin Deficiency in Patients with Untreated Multiple Myeloma Stage II and III.. Blood, 2004, 104, 4861-4861.	0.6	1
36	Donor CD34+ Cell Chimerism at Day 28 and Chronic Graft-Versus-Host Disease (GvHD) but Not High-Risk Cytogenetics Influence Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS.. Blood, 2006, 108, 547-547.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance Of EVI1 expression In Acute Myeloid Leukemia Patients With Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic Hematopoietic Cell Transplantation With Reduced-Intensity Conditioning. <i>Blood</i> , 2013, 122, 3383-3383.	0.6	1
38	Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 640-643.	1.3	0
39	Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma (MM): Preliminary Results of a Phase I Clinical Trial.. <i>Blood</i> , 2004, 104, 4901-4901.	0.6	0
40	Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Conventional Chemotherapy: Final Results of a Phase I Study.. <i>Blood</i> , 2005, 106, 5154-5154.	0.6	0
41	Factors Influencing Relapse after Allogeneic Hematopoietic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS.. <i>Blood</i> , 2007, 110, 1654-1654.	0.6	0
42	Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemias (SAL). <i>Blood</i> , 2008, 112, 2972-2972.	0.6	0
43	Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraC Application Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival. <i>Blood</i> , 2008, 112, 2966-2966.	0.6	0
44	Reduction of Relapse Incidence and Improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status.. <i>Blood</i> , 2009, 114, 1612-1612.	0.6	0
45	Outcome Of MDS and AML With MDS-Related Changes: Treatment Versus Prognostic Factors. <i>Blood</i> , 2013, 122, 5223-5223.	0.6	0
46	High Pri-Mir-181a-1 and Pri-Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning. <i>Blood</i> , 2014, 124, 732-732.	0.6	0
47	Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4398-4398.	0.6	0
48	Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma. <i>Blood</i> , 2015, 126, 5439-5439.	0.6	0
49	Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3829-3829.	0.6	0
50	Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 2573-2573.	0.6	0
51	Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts). <i>Blood</i> , 2015, 126, 5616-5616.	0.6	0
52	High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning. <i>Blood</i> , 2015, 126, 2032-2032.	0.6	0
53	Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies. <i>Blood</i> , 2015, 126, 2517-2517.	0.6	0
54	Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment. <i>Blood</i> , 2016, 128, 5627-5627.	0.6	0

#	ARTICLE	IF	CITATIONS
55	High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 517-517.	0.6	0
56	Absolute Quantification of Pre-microRNA-155 Copy Numbers By Digital Droplet PCR Identifies Acute Myeloid Leukemia (AML) Patients with Adverse Outcome. Blood, 2016, 128, 1698-1698.	0.6	0
57	Biological Associations and Clinical Impact of Differential Expression of the Pre-Mir-29a/b-1 and Pre-Mir-29b-2/C Clusters in Acute Myeloid Leukemia. Blood, 2016, 128, 5110-5110.	0.6	0
58	High Expression of ZBTB7A at Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5092-5092.	0.6	0
59	Unsupervised hierarchical clustering of surface antigen expression to identify normal karyotype AML patients with distinct disease characteristics and poor outcome.. Journal of Clinical Oncology, 2017, 35, 7042-7042.	0.8	0
60	Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39). Blood, 2018, 132, 2064-2064.	0.6	0
61	Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma " AGMT_MM1. Blood, 2018, 132, 3275-3275.	0.6	0
62	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancers, 2021, 13, 5679.	1.7	0